Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

[1]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[2]  J. Trojanowski,et al.  MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. , 2013, ACS medicinal chemistry letters.

[3]  Erin B D Clabough.  Huntington’s Disease: The Past, Present, and Future Search for Disease Modifiers , 2013, The Yale journal of biology and medicine.

[4]  T. Foltynie,et al.  Parkinson’s disease: an update on pathogenesis and treatment , 2013, Journal of Neurology.

[5]  Wim Robberecht,et al.  The changing scene of amyotrophic lateral sclerosis , 2013, Nature Reviews Neuroscience.

[6]  Marileen Dogterom,et al.  Microtubule organization in vitro. , 2013, Current opinion in cell biology.

[7]  Y. Jan,et al.  Golgi Outposts Shape Dendrite Morphology by Functioning as Sites of Acentrosomal Microtubule Nucleation in Neurons , 2012, Neuron.

[8]  J. Trojanowski,et al.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. , 2012, Journal of medicinal chemistry.

[9]  R. Nussbaum,et al.  Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. , 2012, The Journal of clinical investigation.

[10]  T. Ishikawa.  Structural biology of cytoplasmic and axonemal dyneins. , 2012, Journal of structural biology.

[11]  K. Altmann,et al.  Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules. , 2012, Chemistry & biology.

[12]  E. Reddy,et al.  (Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies. , 2012, Journal of medicinal chemistry.

[13]  F. Lee,et al.  Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027 , 2012, The Journal of Neuroscience.

[14]  S. Steinberg,et al.  TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells , 2012, Molecular Cancer Therapeutics.

[15]  J. Trojanowski,et al.  The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice , 2012, The Journal of Neuroscience.

[16]  Mark Ellisman,et al.  LRRK2 Parkinson disease mutations enhance its microtubule association. , 2011, Human molecular genetics.

[17]  F. Obata,et al.  LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth , 2012, PloS one.

[18]  C. Hoogenraad,et al.  Centrosomes, microtubules and neuronal development , 2011, Molecular and Cellular Neuroscience.

[19]  Lihong Hu,et al.  Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers. , 2011, Journal of the American Chemical Society.

[20]  B. Stockwell,et al.  Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency , 2011, ACS medicinal chemistry letters.

[21]  G. Helms,et al.  Identification and biological activities of new taccalonolide microtubule stabilizers. , 2011, Journal of medicinal chemistry.

[22]  E. Masliah,et al.  Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease , 2011, BMC Neuroscience.

[23]  E. Masliah,et al.  Hyperphosphorylated Tau in an α‐synuclein‐overexpressing transgenic model of Parkinson’s disease , 2011, The European journal of neuroscience.

[24]  J. Trojanowski,et al.  The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. , 2011, Pharmacological research.

[25]  A. Sidhu,et al.  Tauopathic Changes in the Striatum of A53T α-Synuclein Mutant Mouse Model of Parkinson's Disease , 2011, PloS one.

[26]  R. Palmiter,et al.  Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model , 2011, The Journal of cell biology.

[27]  C. B. Kunst,et al.  Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[28]  H. Paudel,et al.  Parkinsonian Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and α-Synuclein Mutations Promote Tau Protein Phosphorylation at Ser262 and Destabilize Microtubule Cytoskeleton in Vitro* , 2010, The Journal of Biological Chemistry.

[29]  J. Trojanowski,et al.  Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy , 2010, The Journal of Neuroscience.

[30]  C. Ronchi,et al.  Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+‐induced neurodegeneration , 2010, Journal of neurochemistry.

[31]  C. Galmarini,et al.  Cabazitaxel, a new taxane with favorable properties. , 2010, Drugs of today.

[32]  David C Schriemer,et al.  Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. , 2010, Chemistry & biology.

[33]  Eran Perlson,et al.  Retrograde axonal transport: pathways to cell death? , 2010, Trends in Neurosciences.

[34]  Frank Bradke,et al.  Axon Extension Occurs Independently of Centrosomal Microtubule Nucleation , 2010, Science.

[35]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[36]  R. Gross,et al.  Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? , 2009, Trends in pharmacological sciences.

[37]  Concepción Lillo,et al.  Axonal Stress Kinase Activation and Tau Misbehavior Induced by Kinesin-1 Transport Defects , 2009, The Journal of Neuroscience.

[38]  P. Lienau,et al.  Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. , 2009, Neuro-oncology.

[39]  U. Klar,et al.  Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate , 2008, Expert opinion on investigational drugs.

[40]  D. Mavroudis,et al.  Paclitaxel and docetaxel in the treatment of breast cancer , 2008 .

[41]  A. Grierson,et al.  Role of axonal transport in neurodegenerative diseases. , 2008, Annual review of neuroscience.

[42]  C. Discafani,et al.  TTI-237: a novel microtubule-active compound with in vivo antitumor activity. , 2008, Cancer research.

[43]  Ram Dixit,et al.  Differential Regulation of Dynein and Kinesin Motor Proteins by Tau , 2008, Science.

[44]  C. Shaw,et al.  Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. , 2007, Human molecular genetics.

[45]  M. Goedert,et al.  Interaction of tau protein with the dynactin complex , 2007, The EMBO journal.

[46]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[47]  M. Hellerstein,et al.  Stabilization of Hyperdynamic Microtubules Is Neuroprotective in Amyotrophic Lateral Sclerosis* , 2007, Journal of Biological Chemistry.

[48]  N. Zhang,et al.  2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization. , 2007, Bioorganic & medicinal chemistry letters.

[49]  J. Baselga,et al.  Targeting the microtubules in breast cancer beyond taxanes: the epothilones. , 2007, The oncologist.

[50]  Nan Zhang,et al.  Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. , 2007, Journal of medicinal chemistry.

[51]  I. Barasoain,et al.  Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. , 2007, Nature chemical biology.

[52]  B. C. Carter,et al.  Multiple-motor based transport and its regulation by Tau , 2007, Proceedings of the National Academy of Sciences.

[53]  Arun K. Ghosh,et al.  Synergistic Effects of Peloruside A and Laulimalide with Taxoid Site Drugs, but Not with Each Other, on Tubulin Assembly , 2006, Molecular Pharmacology.

[54]  Ian J. Reynolds,et al.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons , 2006, Neurobiology of Disease.

[55]  Xiao-Jiang Li,et al.  Interaction of Huntingtin-associated Protein-1 with Kinesin Light Chain , 2006, Journal of Biological Chemistry.

[56]  Dan L Sackett,et al.  A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities , 2006, Molecular Cancer Therapeutics.

[57]  S. Reske,et al.  Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD , 2005, Annals of neurology.

[58]  S. Rundlett,et al.  Identification of novel and improved antimitotic agents derived from noscapine. , 2005, Journal of medicinal chemistry.

[59]  Wenhua Liu,et al.  Selective Vulnerability of Dopaminergic Neurons to Microtubule Depolymerization* , 2005, Journal of Biological Chemistry.

[60]  T. Surrey,et al.  The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor , 2005, FEBS letters.

[61]  R. Andersen,et al.  Ceratamines, structurally simple microtubule-stabilizing antimitotic agents with unusual cellular effects. , 2005, Cancer research.

[62]  J. M. Lee,et al.  Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein , 2005, Experimental Neurology.

[63]  Bin Zhang,et al.  Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.

[64]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Kuret,et al.  Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro* , 2004, Journal of Biological Chemistry.

[66]  E. Seeberg,et al.  Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.

[67]  L. Amos,et al.  Microtubule structure and its stabilisation. , 2004, Organic & biomolecular chemistry.

[68]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[69]  Richard G. Brusch,et al.  Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.

[70]  Leslie Wilson,et al.  Differential regulation of microtubule dynamics by three- and four-repeat tau: Implications for the onset of neurodegenerative disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Pomponi,et al.  Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. , 2003, Biochemical pharmacology.

[72]  T. Hemscheidt,et al.  Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity. , 2003, Cancer research.

[73]  H. Neumann.  Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. , 2003, Current opinion in neurology.

[74]  George Perry,et al.  Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. , 2003, The American journal of pathology.

[75]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[76]  Shin J. Oh,et al.  Mutant dynactin in motor neuron disease , 2003, Nature Genetics.

[77]  N. Rusan,et al.  Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. , 2002, Cancer research.

[78]  M. Zucchetti,et al.  A novel taxane active against an orthotopically growing human glioma xenograft , 2001, Cancer.

[79]  K. Altmann.  Microtubule-stabilizing agents: a growing class of important anticancer drugs. , 2001, Current opinion in chemical biology.

[80]  J. Trojanowski,et al.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. , 2001, The American journal of pathology.

[81]  E. Mandelkow,et al.  Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. , 2000, Biochemistry.

[82]  A. Cáceres,et al.  2,4-Dichlorophenoxyacetic acid disrupts the cytoskeleton and disorganizes the Golgi apparatus of cultured neurons. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[83]  S. Haggarty,et al.  Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. , 2000, Chemistry & biology.

[84]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[85]  M. Hutton,et al.  ACCELERATED FILAMENT FORMATION FROM TAU PROTEIN WITH SPECIFIC FTDP-17 MISSENSE MUTATIONS , 1999 .

[86]  S. Lovestone,et al.  Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation , 1999, FEBS letters.

[87]  L. Amos,et al.  How Taxol stabilises microtubule structure. , 1999, Chemistry & biology.

[88]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[89]  M. Goedert,et al.  Tau proteins with FTDP‐17 mutations have a reduced ability to promote microtubule assembly , 1998, FEBS letters.

[90]  J. Holy.  Chlorpropham [isopropyl N-(3-chlorophenyl) carbamate] disrupts microtubule organization, cell division, and early development of sea urchin embryos. , 1998, Journal of toxicology and environmental health. Part A.

[91]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[92]  C. Fairchild,et al.  Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). , 1998, Cancer research.

[93]  K. Ye,et al.  Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  S. Hersch,et al.  Interaction of Huntingtin-Associated Protein with Dynactin P150Glued , 1998, The Journal of Neuroscience.

[95]  P. Worley,et al.  Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. , 1997, Human molecular genetics.

[96]  J. Trojanowski,et al.  Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation , 1997, The Journal of cell biology.

[97]  J. Trojanowski,et al.  Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells) , 1997, The Journal of Neuroscience.

[98]  J. Brion,et al.  Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. , 1996, Journal of neuropathology and experimental neurology.

[99]  Alejandra del C. Alonso,et al.  Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules , 1996, Nature Medicine.

[100]  U. Wagner,et al.  Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. , 1996, Journal of cell science.

[101]  S. Schreiber,et al.  (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. , 1996, Chemistry & biology.

[102]  H. Rosenkranz,et al.  Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. , 1996, Biochemistry.

[103]  E. Mandelkow,et al.  Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. , 1995, Molecular biology of the cell.

[104]  J. Trojanowski,et al.  Microtubule stabilizing drugs for the treatment of Alzheimer's disease , 1994, Neurobiology of Aging.

[105]  E D Salmon,et al.  Brain microtubule-associated proteins modulate microtubule dynamic instability in vitro. Real-time observations using video microscopy. , 1992, Journal of cell science.

[106]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[107]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[108]  R. A. Crowther,et al.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease , 1989, Neuron.

[109]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[110]  R. Himes,et al.  Rotenone inhibition of tubulin self-assembly. , 1978, Biochimica et biophysica acta.

[111]  B. Brinkley,et al.  Rotenone inhibition of spindle microtubule assembly in mammalian cells. , 1974, Experimental cell research.

[112]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[113]  M. Kidd.  Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease , 1963, Nature.

[114]  Christine Klein,et al.  Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[115]  M. Piccart-Gebhart,et al.  Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer , 2010, Nature Reviews Clinical Oncology.

[116]  K. Altmann.  The epothilones : an outstanding family of anti-tumor agents : from soil to the clinic , 2009 .

[117]  A. F. Soleng,et al.  A thorny question: how does activity maintain dendritic spines? , 1999, Nature Neuroscience.

[118]  Toshimasa Tanaka,et al.  GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol , 1997, Cancer Chemotherapy and Pharmacology.

[119]  T. Mitchison,et al.  Microtubule polymerization dynamics. , 1997, Annual review of cell and developmental biology.

[120]  B. Hyman,et al.  Differential effect of three‐repeat and four‐repeat tau on mitochondrial axonal transport , 2009, Journal of neurochemistry.